$Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia$

Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company...

3d ago

AFMD

Affimed says first patient dosed in Phase 1 study of AFM28

Affimed announced that the first patient was dosed in a Phase 1 multicenter, open label, first-in-human dose escalation...

3d ago

AFMD

Affimed assumed with an Overweight at Wells Fargo

Wells Fargo assumed coverage of Affimed with an Overweight rating and $7 price target, with no changes made...

5d ago

AFMD

Affimed price target lowered to $1 from $2 at Stifel

Stifel lowered the firm’s price target on Affimed to $1 from $2 and keeps a Hold rating on...

8d ago

AFMD

See More AFMD News >

Financials

Annual

Income Statement >

0HL9 FAQ

What was Affimed’s price range in the past 12 months?

Affimed lowest stock price was $0.65 and its highest was $5.04 in the past 12 months.

What is Affimed’s market cap?

Currently, no data Available

When is Affimed’s upcoming earnings report date?

Affimed’s upcoming earnings report date is Jun 28, 2023 which is in 88 days.

How were Affimed’s earnings last quarter?

Affimed released its earnings results on Mar 23, 2023. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.208 by -$0.032.

Is Affimed overvalued?

According to Wall Street analysts Affimed’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Affimed pay dividends?

Affimed does not currently pay dividends.

What is Affimed’s EPS estimate?

Affimed’s EPS estimate is -$0.21.

How many shares outstanding does Affimed have?

Currently, no data Available

What happened to Affimed’s price movement after its last earnings report?

Affimed reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.208. Following the earnings report the stock price went down -9.342%.

Which hedge fund is a major shareholder of Affimed?

Among the largest hedge funds holding Affimed’s share is Baker Bros Advisors LP. It holds Affimed’s shares valued at 8M.

---

Affimed Stock Smart Score

Neutral

Fundamentals

Return on Equity

-56.68%

Trailing 12-Months

Asset Growth

-16.42%

Trailing 12-Months

The Affimed Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Learn more about TipRanks Smart Score

Go to Top Smart score Stocks >

Company Description

Affimed

Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

---